Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tivdak

Chemical Nametisotumab vedotin-tftv
Dosage FormLyophilized powder (intravenous; 40 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanySeagen
Approval Year2021

Indication

  • For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Last updated on 4/25/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivdak (tisotumab vedotin-tftv) Prescribing Information.2021Seagen Inc., Bothell, WA
Document TitleYearSource
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.2021The Lancet Oncology
Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer.2020Clinical Cancer Research